(欧文原著)

1. NakayamaK, Ishibashi T, Ishikawa M, KatagiriA, Katagiri H, Iida K, Nakayama N, MiyazakiK.: Microwave endometrial ablation at a frequency of 2.45 GHz for menorrhagia: Analysis of treatment results at a single facility.
J Obstet Gynaecol Res., 2013 in press

2. Nakayama K, Ishikawa M, Katagiri H, Katagiri A, Ishibashi T, Iida K, Nakayama N, Miyazaki K.: Surgical treatment outcomes of serious chronic tubo-ovarian abscess: A single-center series of 20 cases.
Clin Exp Obstet Gynecol.,2013 in press

3. Rahman MT, Nakayama K, Rahman M, Ishikawa M, Katagiri H, Katagiri A, Ishibashi T, Sato E, Iida K, Nakayama N, Ishikawa N, Miyazaki K.: ESR1 gene amplification in endometrial carcinomas: A clinicopathological analysis.
Anticancer Res., 33: 3775-3781, 2013

4. Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Sato E, Iida K, Nakayama N, Ishikawa N, Miyazaki K.: KRAS and MAPK1 gene amplification in type II ovarian carcinomas.
Int J Mol Sci., 14: 13748-13762, 2013

5. Rahman MT, Nakayama K, Ishikawa M, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Iida K, Miyazaki K.: Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
Oncology, 84: 166-173, 2013

6. Rahman M, Nakayama K, Rahman MT, Nakayama N, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Otsuki Y, Nakayama S, Miyazaki K.: PPP2R1Amutation is a rare event in ovarian carcinoma across histological subtypes.
Anticancer Res., 33: 113-118, 2013

7. KatagiriH, NakayamaK, Rahman MT, Rahman M, KatagiriA, IshibashiT, IshikawaM, IidaK, NakayamaS, OtsukiY, MiyazakiK.: Is ATP7B a predictive marker in patients with ovarian carcinoma treated with platinum-taxane combination chemotherapy?
Int J Gynecol Cancer, 23: 60-64,2013

8. Rahman M, Nakayama K, Rahman MT, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Miyazaki K.: Clinicopathological analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer.
Hum Pathol.,44: 103-109, 2013

9. Kanasaki H, Oride A, Nakayama K, Miyazaki K.: Evaluation of immediate laparoscopic surgery for gynecologic disoerders.
Gynecol Surg., 9: 111-115, 2012

10.Nishi T, Maruyama R, Urano T, Nakayama N, Kawabata Y, Yano S, Yoshida M, Nakayama
K, Miyazaki K, Takenaga K, Tanaka T, Tajima Y.: Low expression of nucleus
accumbens-associated protein 1 predicts poor prognosis for patients with pancreatic ductal
adenocarcinoma.
Pathol Int.,62: 802-810,2012

11.Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Kurman RJ, Levine DA, Wang TL, Shih IeM.: Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
J Natl Cancer Inst., 104: 1503-1513, 2012

12.YapKL, FraleySI, ThiavilleMM, JinawathN, NakayamaK, WangJ, WangTL, WirtzD, ShihIeM.: NAC1 is an actin-binding protein that is essential for effective cytokinesis in cancer cells.
Cancer Res., 72: 4085-4096, 2012

13.Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Nakayama S, Otsuki S, Miyazaki K.: Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer.
Am J Clin Pathol., 138: 535-544, 2012

14.Rahman MT, Nakayama K, Ishikawa M, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Iida K, Yamada T, Miyazaki K.: NAC1, a BTB/POZ protein overexpressed in uterine sarcomas.
Anticancer Res., 32: 3841-3845, 2012

15.Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Nakayama N, Otsuki Y, Nakayama S, Miyazaki K.: Gene amplification of ZNF217 located at chr20q13.2 is associated with lymph node metastasis in ovarian clear cell carcinoma.
Anticancer Res., 32: 3091-3095, 2012

16.Rahman M, Nakayama K, Rahman MT, Nakayama N, Ishikawa M, Katagiri A, Iida K, Nakayama S, Otsuki Y, Shih IeM, Miyazaki K.: Clinicopathologic and biological analysis of PIK3CAmutationin ovarian clear cell carcinoma.
Hum Pathol., 43: 2197-2206, 2012

17.Okazaki K, Nakayama N, Nariai Y, Nakayama K, Miyazaki K, Maruyama R, Kato H, Kosugi S, Urano T, Sakashita G.: Nuclear localization signal in a cancer-related transcriptional regulator protein NAC1.
Carcinogenesis, 33: 1854-1862, 2012

18.Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Nakayama N, Otsuki Y, Nakayama S, Miyazaki K.: Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas.
Br J Cancer, 107: 300-307, 2012

19.KatagiriA, NakayamaK, Rahman MT, Rahman M, KatagiriH, IshikawaM, IshibashiT, IidaK, OtsukiY, NakayamaS, MiyazakiK.: Frequent loss of tumor suppressor ARID1A protein expression in adenocarcinomas/adenosquamouscarcinomas of the uterine cervix.
Int J Gynecol Cancer,22: 208-212, 2012

20.Rahman MT, NakayamaK, Rahman M, Nakayama N, IshikawaM, KatagiriA, IidaK, Nakayama S, OtsukiY, Shih IeM, MiyazakiK.: Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma.
Cancer,118: 2846-2857, 2012

21.Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Shih IeM.: Low-grade serous carcinomas of the ovary contain very few point mutations.
J Pathol., 226: 413-420, 2012

22.KatagiriA, NakayamaK, Rahman MT, Rahman M, KatagiriH, NakayamaN IshikawaM, IshibashiT, IidaK, OtsukiY, NakayamaS, MiyazakiK.: Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
Mod Pathol.,25: 282-288,2012

23.Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Otsuki Y, Kobayashi H, Nakayama S, Miyazaki K.: Biological and clinical significance of NAC1 expression in cervical carcinomas: a comparative study between squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas.
Hum Pathol.,43: 506-519, 2012

24.Iida K, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Yeasmin S, Otsuki Y, Kobayashi H, Nakayama S, Miyazaki K.: EGFRgene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.
Br J Cancer, 105: 420-427, 2011

25.Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Miyazaki K.: MKK4 acts as a potential tumor suppressor in ovarian cancer.
Tumour Biol., 32: 661-670, 2011

26.Shih IeM, Nakayama K, Wu G, Nakayama N, Zhang J, Wang TL.: Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma.
Mod Pathol.,24: 638-645, 2011

27.Nakayama K, Yeasmin S, Katagiri A, Rahman MT, Rahman M, Ishikawa M, Iida K,
Nakayama N, Aoki S, Miyazaki K.: A comparative study between microwave endometrial ablation and conventional surgical procedures for treatment of menorrhagia.
Clin Exp Obstet Gynecol., 38: 33-37, 2011

28.Nakayama K, Rahman MT, Rahman M, Ishikawa M, Yeasmin S, Katagiri A, Iida K, Nakayama N, Aoki S, Miyazaki K.: Microwave endometrial ablation is a highly efficacious way to emergently control life-threatening uterine hemorrhage.
Arch Gynecol Obstet., 283: 1065-1068, 2011

29.Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Miyazaki K.: Loss of MKK4 expression in ovarian cancer: a potential role for the epithelial to mesenchymal transition.
Int J Cancer, 128: 94-104, 2011

30.Ishikawa M, Nakayama K, Rahman MT, Rahman M, Katagiri A, Iida K, Miyazaki K.: Functional and clinicopathological analysis of loss of MKK4 expression in endometrial cancer.
Oncology,79: 238-246, 2010

31.Nakayama K, Rahman MT, Rahman M, Yeasmin S, Ishikawa M, Katagiri A, Iida K,
Nakayama N, Miyazaki K.: Biological role and prognostic significance of NAC1 in ovarian
cancer.
Gynecol Oncol., 119: 469-478, 2010

32.Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N.: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Science, 330: 228-231, 2010

33.Katagiri A, Nakayama K, Rahman MT, Rahman M, Yeasmin S, Ishikawa M, Iida K, Nakayama N, Miyazaki K.: MEK inhibition suppresses cell invasion and migration in ovarian cancers with activation of ERK1/2.
Exp Ther Med.,1: 591-596, 2010

34.Nakayama K, Nagai Y, Ishikawa M, AokiY, Miyazaki K.: Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer.
Int J Clin Oncol.,15: 440-446, 2010

35.Ishikawa M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Miyazaki K.: NAC1,
a potential stem cell pluripotency factor expression in normal endometrium, endometrial
hyperplasia and endometrial carcinoma.
Int J Oncol., 36: 1097-1103, 2010

36.Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Iida K, Otsuki Y, Kobayashi
H, Nakayama S, Miyazaki K.: Expression of nuclear Notch3 in cervical squamous cell
carcinomas and its association with adverse clinical outcomes.
Gynecol Oncol., 117: 409-416, 2010

37.Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K.: Gene amplification CCNE1is related to poor survival and potential therapeutic target in ovarian cancer.
Cancer, 116: 2621-2634, 2010

38.Nakayama K, Ishikawa M, Nagai Y, Yaegashi N, Aoki Y, Miyazaki K.: Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate.
Int J Clin Oncol.,15: 179-183, 2010

39.Kuo KT, Mao TL, Chen X, Feng Y, Nakayama K, Wang Y, Glas R, Ma MJ, Kurman RJ, Shih IeM, Wang TL.: DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma.
Clin Cancer Res.,16: 1997-2008, 2010

40.Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Miyazaki K.: Expression of a BTB/POZ protein, NAC1, is essential for the proliferation of normal cyclic endometrial glandular cells and is up-regulated by estrogen.
Clin Cancer Res., 15: 804-811, 2009

41.Nakayama K, Nakayama N, Ishibashi M, Yeasmin S, Fukumoto M, Miyazaki K.: Fractional
allelic loss as a potential biomarker of risk prediction in early-stage mucinous ovarian tumors of low malignant potential.
Eur J Gynaecol Oncol.,30: 16-19, 2009

42.Jinawath N, Vasoontara C, Yap KL, Thiaville MM, Nakayama K, Wang TL, Shih IM.: NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway.
Oncogene,28: 1941-1948, 2009

43.Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M,
Miyazaki K.: KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
Br J Cancer, 99: 2020-2028, 2008

44.Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Fukumoto M,
Miyazaki K.: A BTB/POZ protein, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
Clin Cancer Res.,14: 3149-3155, 2008

45.Yeasmin S, Nakayama K, Ishibashi M, Katagiri A, Iida K, Purwana IN, Nakayama N,
Miyazaki K.: Expression of the bric-a-brac tramtrack broad complex protein NAC-1 in
cervical carcinomas seems to correlate with poorer prognosis.
Clin Cancer Res.,14: 1686-1691, 2008

46.Huan Z, Nakayama K, Nakayama N, Ishibashi M, Yeasmin S, Katagiri A, Purwana IN, Iida
K, Maruyama R, Fukumoto M, Miyazaki K.: Genetic classification of ovarian carcinoma based on microsatellite analysis: relationship to clinicopathological features and patient survival.
Oncol Rep.,19: 775-781, 2008

47.Nakayama K, Nakayama N, Wang TL, Shih IeM.: NAC-1 controls cell growth and survival by repressing transcription of Gadd45GIP1, a candidate tumor suppressor.
Cancer Res.,67: 8058-8064, 2007

48.Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih IeM, Wang TL.:
Amplicon profiles in ovarian serous carcinomas.
Int J Cancer,120: 2613-2617, 2007

49.Nakayama K, Nakayama N, Davidson B, Sheu JJ, Jinawath N, Santillan A, Salani R, Bristow RE, Morin PJ, Kurman RJ, Wang TL, Shih IeM.: A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival.
Proc Natl Acad Sci USA., 103: 18739-18744, 2006

50.Park JT, Li M, Nakayama K, Mao TL, Davidoson B, Zhang Z, Kurman RJ, Eberhart CG, Shih
IeM, Wang TL.: Notch3 gene amplification in ovarian cancer.
Cancer Res., 66: 6312-6318, 2006

51.Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, Samuels Y, Velculescu VE, Wang TL, Shih IeM.: Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
Cancer Biol Ther.,5: 779-785, 2006

52.Nakayama K, Nakayama N, Davidoson B, Katabuchi H, Kurman RJ, Velculescu VE, Shih IeM, Wang TL.: Homozygous deletion of MKK4 in ovarian serous carcinoma.
Cancer Biol Ther., 5: 630-634, 2006

53.Konishi K, Takimoto M, Kaneko K, Makino R, Hirayama Y, Nozawa H, Kurahashi T,
Kumekawa Y, Yamamoto T, Ito H, Yoshikawa N, Kusano M, Nakayama K, Rembacken BJ,
Ota H, Imawari M.: BRAF mutations and phosphorylation status of mitogen-activated protein
kinases in the development of flat and depressed-type colorectal neoplasias.
Br J Cancer,94: 311-317, 2006

54.Shih IeM, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, Vang R, Parmigiani G,
Kurman RJ, Trope CG, Davidson B, Wang TL.: Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma.
Proc Natl Acad Sci USA., 102: 14004-14009, 2005

55.Aida T, Takebayashi Y, Shimizu T, Okamura C, Higashimoto M, Kanzaki A, Nakayama K, Terada K, Sugiyama T, Miyazaki K, Ito K, Takenoshita S, Yaegashi N.: Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma.
Gynecol Oncol., 97: 41-45, 2005

56.Konishi K, Yamochi T, Makino R, Kaneko K, Yamamoto T, Nozawa H, Katagiri A, Ito H, Nakayama K, Ota H, Mitamura K, Imawari M.: Molecular differences between sporadic serrated and conventional colorectal adenomas.
Clin Cancer Res.,10: 3082-3090, 2004

57.Nakayama K, Kanzaki A, Terada K, Mutoh M, Ogawa K, Sugiyama T, Takenoshita S, Itoh K,
Yaegashi N, Miyazaki K, Neamati N, Takebayashi Y.: Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy.
Clin Cancer Res., 10: 2804-2811, 2004

58.Hata K, Nakayama K, Fujiwaki R, Katabuchi H, Okamura H, Miyazaki K.: Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer.
Gynecol Oncol., 93: 215-222, 2004

59.Nakayama K,Takebayashi Y, Hata K, Fujiwaki R, Iida K, Fukumoto M, Miyazaki K.: Allelic
loss at 19q12 and Xq11-12 predict an adverse clinical outcome in patients with mucinous ovarian tumours of low malignant potential.
Br J Cancer, 90: 1204-1210, 2004

60.Hata K, Osaki M, Dhar DK, Nakayama K, Fujiwaki R, Ito H, Nagasue N, Miyazaki K.:
Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.
Cancer Chemother Pharmacol.,53: 68-74, 2004

61.Kanzaki A, Nakayama K, Miyashita H, Shirata S, Nitta Y, Oubu M, Higashimoto M, Mutoh M, Mori S, Konno S, Ogawa K, Toi M, Takebayashi Y.: Mutation analysis of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinomas.
Anticancer Res., 23:1913-1915, 2003

62.Nakayama K, Takebayashi Y, Hata K, Fujiwaki R, Iida K, Fukumoto M, Miyazaki K.: The
proliferative activity of ovarian tumors of low malignant potential differs from that of ovarian carcinoma.
Anticancer Res., 23: 4657-4662, 2003

63.Fujiwaki R, Iida K,Nakayama K,Kanasaki H, Ozaki T, Hata K, Sakai E, Miyazaki K.:
Dihydropyrimidine dehydrogenase in normal and malignant endometrium: relationship with cell proliferation and thymidine phosphorylase.
Virchows Arch.,443: 672-677, 2003

64.Fujiwaki R, Iida K, Nakayama K, Kanasaki H, Hata K, Katabuchi H, Okamura H, Miyazaki K.: Clinical significance of interleukin-1 receptor antagonist in patients with cervical carcinoma.
Gynecol Oncol., 89: 77-83. 2003

65.Hata K, Osaki M, Kanasaki H,Nakayama K, Fujiwaki R, Ito H, Miyazaki K.: Induction of thymidine phosphorylase expression and enhancement of Furtulon sensitivity by Taxol in a human ovarian carcinoma cell line.
Anticancer Res., 23: 2665-2669, 2003

66.Hata K, Dhar DK, Kanasaki H, Nakayama K, Fujiwaki R, Katabuchi H, Okamura H, Nagasue
N, Miyazaki K.: Serum endostatin levels in patients with epithelial ovarian cancer.
Anticancer Res., 23: 1907-1912, 2003

67.Hata K, Osaki M, Kanasaki H, Nakayama K, Fujiwaki R, Ito H, Miyazaki K.: Induction of
thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line.
Anticancer Res., 23: 1525-1531, 2003

68.Nakayama S, Nakayama K, Takebayashi Y, Hata K, Fujiwaki R, Fukumoto M,Miyazaki K.:
Allelotypes as potential prognostic markers in ovarian carcinoma treated with cisplatin-based chemotherapy.
Int J Mol Med., 11: 621-625, 2003

69.Nakayama K, Takebayashi Y, Nakayama S, Hata K, Fujiwaki R, Fukumoto M,Miyazaki K.: Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin.
Cancer Lett.,192: 227-235, 2003

70.Miyashita H, Nitta Y, Mori S, Kanzaki A, Nakayama K, Terada K, Sugiyama T, Kawamura H,
Sato A, Morikawa H, Motegi K, Takebayashi Y.: Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin.
Oral Oncol.,39: 157-162, 2003

71.Nakayama K,Kanzaki A, Ogawa K, Miyazaki K,Neamati N, Takebayashi Y.: Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.
Int J Cancer,101: 488-495, 2002

72.Hata K, Udagawa J, Fujiwaki R, Nakayama K, Otani H, Miyazaki K.: Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer.
Oncology,62: 340-348, 2002

73.Fujiwaki R, Hata K, Nakayama K, Moriyama M, Iwanari O, Katabuchi H, Okamura H, Sakai E, Miyazaki K.: Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes.
Int J Cancer,99: 328-335, 2002

74.Nakayama K,Kanzaki A, Hata K, Katabuchi H, Okamura H, Miyazaki K, Fukumoto M, Takebayashi Y.: Hypoxia-inducible factor 1 alpha(HIF-1 alpha)gene expression in human ovarian carcinoma.
Cancer Lett.,176: 215-223, 2002

75.Kanzaki A, Toi M, Neamati N, Miyashita H, Oubu M, Nakayama K, Bando H, Ogawa K, Mutoh M, Mori S, Terada K, Sugiyama T, Fukumoto M, Takebayashi Y.: Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma.
Jpn J Cancer Res., (現: Cancer Sci.) 93: 70-77, 2002

76.Nakayama K, Takebayashi Y, Namiki T, Tamahashi N, Nakayama S, Uchida T, Miyazaki K,
Fukumoto M.: Comprehensive allelotype study of ovarian tumors of low malignant potential:
potential differences in pathways between tumors with and without genetic predisposition to
invasive carcinoma.
Int J Cancer,94: 605-609, 2001

77.Takebayashi Y, Nakayama K, Kanzaki A, Miyashita H, Ogura O, Mori S, Mutoh M, Miyazaki K, Fukumoto M, Pommier Y.: Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors.
Cancer Lett., 174: 115-125, 2001(Nakayama K, Takebayashi Y, equal contributors)

78.Nakayama K, Miyazaki K, Kanzaki A, Fukumoto M, Takebayashi Y.: Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines.
Oncol Rep., 8: 1285-1287, 2001

79.Miyashita H, Mori S, Tanda N, Nakayama K, Kanzaki A, Sato A, Morikawa H, Motegi K, Takebayashi Y, Fukumoto M.: Loss of heterozygosity of nucleotide excision repair factors in sporadic oral squamous cell carcinoma using microdissected tissue.
Oncol Rep., 8: 1133-1138, 2001

80.Hata K, Fujiwaki R, Nakayama K, Miyazaki K.: Expression of the Endostatin gene in epithelial ovarian cancer.
Clin Cancer Res., 7: 2405-2409, 2001

81.Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y,
Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y.: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.
Nature Med.,7: 961-966, 2001

82.Nakayama K,Kanzaki A, Takebayashi Y, Toi M, Bando H, Nabei T, Miyazaki K, Fukumoto M.: Different features of angiogenesis between ovarian and breast carcinoma.
Cancer Lett.,170: 161-167, 2001

83.Kanzaki A, Toi M,Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M, Takebayashi Y.:
Expression of multidrug resistance-related transporters in human breast carcinoma.
Jpn J Cancer Res., (現 Cancer Sci.) 92: 452-458, 2001

84. Nakayama K, Konno M, Kanzaki A, Morikawa T, Miyashita H, Fujioka T, Uchida T, Miyazaki
K, Takao S, Aikou T, Fukumoto M, Takebayashi Y.: Allelotype analysis of gallbladder carcinoma associated with anomalous junction of pancreaticobiliary duct.
Cancer Lett., 166: 135-141, 2001

85.Takebayashi Y, Nakayama K, Fujioka T, Kanzaki A, Mutho M, Uchida T, Miyazaki K, Ito M, Fukumoto M.: Expression of multidrug resistance associated transporters (MDR1, MRP1, LRP and BCRP) in porcine oocyte.
Int J Mol Med.,7: 397-400, 2001

86.Hata K, Fujiwaki R, Nakayama K, Maede Y, Fukumoto M, Miyazaki K.: Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor.
Anticancer Res., 20: 3941-3949, 2000

87.Fujiwaki R, Hata K, Nakayama K, Fukumoto M, Miyazaki K.: Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer.
J Clin Oncol.,18: 3946-3951, 2000

88.Hata K, Takebayashi Y, Akiba S, Fujiwaki R, Iida K, Nakayama K, Nakayama S, Fukumoto M,
Miyazaki K.: Expression of the adrenomedullin gene in epithelial ovarian cancer.
Mol Hum Reprod.,6: 867-872, 2000

89.Fujiwaki R, Hata K,Nakayama K, Fukumoto M, Miyazaki K.: Thymidylate synthase expression in epithelial ovarian cancer: relationship with thymidine phosphorylase expression and prognosis.
Oncology, 59: 152-157, 2000

90.Hata K, Fujiwaki R, Maede Y,Nakayama K, Fukumoto M, Miyazaki K.: Expression of thymidinephosphorylase in epithelial ovarian cancer: correlation with angiogenesis, apoptosis, and ultrasound-derived peak systolic velocity.
Gynecol Oncol., 77: 26-34, 2000

91.Hata K, Fujiwaki R, Nakayama K, Fukumoto M, Miyazaki K.: Expression of TP and TIE2 genes in normal ovary with corpus luteum and in ovarian cancer: correlation with ultrasound-derived peak systolic velocity.
Mol Hum Reprod.,6: 319-323, 2000



(欧文症例報告)

1.Rahman M, NakayamaK, Rahman MT, Ishikawa M, Katagiri H, KatagiriA, Sato E, Iida K,
MiyazakiK.: Non-Hodgkin lymphoma of the female genital tract mimicking primary gynecological tumors: A single-center series of 3 cases.
Eur J Gynaecol Oncol., 2013 in press

2.Nakamura K, NakayamaK, MiuraH, Fujiwaki R, ManabeA, Teshima S, NagaiY, MiyazakiK, SawadaK.: Malignant female adnexal tumor of Wolffian origin (FATWO) positive for CD56: a possible diagnostic role for the biomarker.
Eur J Gynaecol Oncol., 2013 in press

3.Ishikawa M, Nakayama K, Rahman MT, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Sato E, Iida K, Nakayama N, Miyazaki K.:Therapy-related myelodysplastic syndrome and acute myeloid leukemia following chemotherapy (paclitaxel and carboplatin) and radiation therapy in ovarian cancer: A case report.
Eur J Gynaecol Oncol., 2013 in press

4.Ishibashi T, Nakayama K, Nakayama N, Katagiri H, Ishikawa N, Miyazaki K.: Perivascular epithelial cell tumor arising from polypoid adenomyoma: a case report.
Eur J Gynaecol Oncol., 34: 104-106, 2013

5.Rahman M, NakayamaK, Ishibashi T, Ishikawa M, Rahman MT, Katagiri H, KatagiriA, Iida K, Kikuchi Y, MiyazakiK.: A case of stage IIIc ovarian clear cell carcinoma: The role for predictive biomarkers and targeted therapies.
Int J Mol Sci., 14: 6067-6073, 2013

6.Rahman MT, Nakayama K, Rahman M, Nakayama N, Ishikawa M, Katagiri A, Katagiri H, Ishibashi T, Iida K, Miyazaki K.: Sister Mary Joseph's nodule associated with rare endometrial squamous cell carcinoma.
Arch Gynecol Obstet., 286: 711-715, 2012

7.Rahman M, NakayamaK, Rahman MT, Katagiri H, Ishibashi T, MiyazakiK.: Enlarged Virchow’s node as a an initial complaint of serous ovarian adenocarcinoma.
Eur J Gynaecol Oncol., 33: 546-548, 2012

8.NakayamaK, Nakayama N, Rahman MT, Rahman M, Katagiri H, KatagiriA, IshikawaM,
Ishibashi T, IidaK, Harada Y, MiyazakiK.: Uterine leiomyosarcoma producing granulocyte
colony stimulating factor.
Int J Gynecol Pathol., 31: 172-177, 2012


9.Yeasmin S,Nakayama K, Katagiri A, Ishikawa M, Iida K, Nakayama N, Miyazaki K.: Exaggerated placental site mimicking placental site trophoblastic tumor: case report and literature review.
Eur J Gynaecol Oncol.,31: 586-589, 2010

10.Yeasmin S,Nakayama K, Ishikawa M, Nakayama N, Miyazaki K.:A case of bilateral pelvic
lymph node involvement in stage Ia1 squamous cell carcinoma of cervix and a review of the literatures.
Int J Clin Oncol.,14: 564-567, 2009

11.Yeasmin S,Nakayama K, Ishibashi M, Katagiri A, Iida K, Manabe A, Nabika T, Nakayama N, Miyazaki K.: Primary osteosarcoma of ovary.
Int J Clin Oncol., 14: 163-166, 2009

12.Yeasmin S,Nakayama K, Ishibashi M, Katagiri A, Iida K, Nakayama N, Aoki S, Kanaoka Y,
Miyazaki K.: Microwave endometrial ablation as an alternative to hysterectomy for the emergent control of uterine bleeding in patients who are poor surgical candidates.
Arch Gynecol Obstet.,280: 279-282, 2009

13.Yeasmin S,Nakayama K, Oride A, Ishibashi M, Ishikawa N, Katagiri A, Iida K, Nakayama N, Miyazaki K.: A case of extrelmely chemoresistant pure pleomorphic rhabdomyosarcoma of the uterus associated with a high serum LDH level.
Eur J Gynaecol Oncol., 29: 518-522, 2009

14.Yeasmin S,Nakayama K, Ishibashi M, Oride A, Katagiri A, Purwana IN, Iida K, Nakayama N, Ishikura H, Miyazaki K.: Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel- and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review.
Int J Gynecol Cancer,18: 1371-1376, 2008



(欧文総説)

1.Nakayama K, Nakayama N, Miyazaki K.: Development of a novel ovarian cancer molecular
target therapy against cancer related transcriptional factor, NAC1.
J Obstet Gynaecol Res., 39: 18-25, 2013

2.Nakayama K, Nakayama N, Katagiri H, Miyazaki K.: Mechanisms of ovarian cancer metastasis: biochemical pathways.
Int J Mol Sci., 13: 11705-11717, 2012

3.Nakayama K, Nakayama N, Ishikawa M, Miyazaki K.: Endometrial serous carcinoma: its
molecular characteristics and histology-specific treatment strategies.
Cancers,4: 799-807, 2012

4.Fukumoto M, Nakayama K.: Ovarian epithelial tumors of low malignant potential: are they precursors of ovarian carcinoma?
Pathol Int.,56: 233-239, 2006




(欧文 その他)

1.Nakayama K, Miyazaki K Kanaoka Y.: Microwave endometrial ablation for hypermenorrhea treatment : a new era in Japan.
Clin Exp Obstet Gynecol.,2013 in press

2.Nakayama K, Nakayama N, Miyazaki K.:Molecular targeting therapy for ovarian cancer;
present condition and future prospective.
Austral-Asian Journal of Cancer, 11: 232-234, 2012

3.Nakayama K, Nakayama N, Miyazaki K.:MAP2K4 (mitogen-activated protein kinase kinase 4).
Atlas Genet Cytogenet Oncol Haematol., 2012
http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html

4.Shih IeM, Ho CM, Nakayama K, Salani R.: Pathogenesis and New Therapeutic Targets of
Ovarian Cancer.
J Oncol., Epub 2012 Aug 30. 2012

5.Nakayama K, Nakayama N, Wang TL.: GADD45GIP1 (growth arrest and DNA-damage-inducible, gamma interacting protein 1).
Atlas Genet Cytogenet Oncol Haematol., 2009
http://AtlasGeneticsOncology.org/Genes/GADD45GIP1ID40668ch19p13.html